Literature DB >> 11956196

Identification of a cis-acting element for the regulation of SMN exon 7 splicing.

Hiroshi Miyajima1, Hidenobu Miyaso, Masayo Okumura, Junko Kurisu, Kazunori Imaizumi.   

Abstract

Spinal muscular atrophy results from the loss of functional survival motor neuron (SMN1) alleles. Two nearly identical copies of SMN exist and differ only by a single non-polymorphic C to T transition in exon 7. This transition leads to alteration of exon 7 splicing; that is, SMN1 produces a full-length transcript, whereas SMN2 expresses a low level of full-length transcript and predominantly an isoform lacking exon 7. The truncated transcript of SMN encodes a less stable protein with reduced self-oligomerization activity that fails to compensate for the loss of SMN1. In this paper, we identified a cis-acting element (element 1), which is composed of 45 bp in intron 6 responsible for the regulation of SMN exon 7 splicing. Mutations in element 1 or treatment with antisense oligonucleotides directed toward element 1 caused an increase in exon 7 inclusion. An approximately 33-kDa protein was demonstrated to associate with a pre-mRNA sequence containing both element 1 and the C to T transition in SMN exon 7 but not with the sequence containing mutated element 1, suggesting that the binding of the approximately 33-kDa protein plays crucial roles in the skipping of SMN exon 7 containing the C to T transition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956196     DOI: 10.1074/jbc.M200851200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes.

Authors:  Natalia N Singh; Elliot J Androphy; Ravindra N Singh
Journal:  RNA       Date:  2004-08       Impact factor: 4.942

2.  Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.

Authors:  Natalia N Singh; Brian M Lee; Ravindra N Singh
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

Review 3.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

4.  Molecular basis of purine-rich RNA recognition by the human SR-like protein Tra2-β1.

Authors:  Antoine Cléry; Sandrine Jayne; Natalya Benderska; Cyril Dominguez; Stefan Stamm; Frédéric H-T Allain
Journal:  Nat Struct Mol Biol       Date:  2011-03-13       Impact factor: 15.369

5.  High-throughput analysis revealed mutations' diverging effects on SMN1 exon 7 splicing.

Authors:  Přemysl Souček; Kamila Réblová; Michal Kramárek; Lenka Radová; Tereza Grymová; Pavla Hujová; Tatiana Kováčová; Matej Lexa; Lucie Grodecká; Tomáš Freiberger
Journal:  RNA Biol       Date:  2019-06-19       Impact factor: 4.652

6.  Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Gene Hung; Frank Rigo; Marco A Passini; C Frank Bennett; Adrian R Krainer
Journal:  Genes Dev       Date:  2010-07-12       Impact factor: 11.361

7.  Optimization of Morpholino Antisense Oligonucleotides Targeting the Intronic Repressor Element1 in Spinal Muscular Atrophy.

Authors:  Erkan Y Osman; Charles W Washington; Kevin A Kaifer; Chiara Mazzasette; Teresa N Patitucci; Kyra M Florea; Madeline E Simon; Chien-Ping Ko; Allison D Ebert; Christian L Lorson
Journal:  Mol Ther       Date:  2016-07-09       Impact factor: 11.454

Review 8.  Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy.

Authors:  Rachel Nlend Nlend; Kathrin Meyer; Daniel Schümperli
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 9.  Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.

Authors:  Natalia N Singh; Brian M Lee; Christine J DiDonato; Ravindra N Singh
Journal:  Future Med Chem       Date:  2015-09-18       Impact factor: 3.808

Review 10.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.